MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels

Chiara Fenoglio, Daniela Galimberti, Carlo Lovati, Ilaria Guidi, Alberto Gatti, Sergio Fogliarino, Marco Tiriticco, Claudio Mariani, Gianluigi Forloni, Carla Pettenati, Pierluigi Baron, Giancarlo Conti, Nereo Bresolin, Elio Scarpini

Research output: Contribution to journalArticlepeer-review


MCP-1 levels are increased in CSF of patients with Alzheimer's disease (AD) compared with controls, suggesting a role in the development of dementia. Recently, a biallelic A/G polymorphism in the MCP-1 promoter at position -2518 has been found, influencing the level of MCP-1 expression in response to an inflammatory stimulus. The distribution of the A-2518G SNP was determined in 269 AD patients and in 203 healthy age matched controls, showing no differences between the two groups. On the contrary, a significant increase of MCP-1 serum levels in AD patients carrying at least one G mutated allele was observed. Moreover, the highest peaks of MCP-1 serum levels were present in patients carrying two G alleles. Stratifying by ApoE genotype, gender or age at onset, no differences in both allele frequency and MCP-1 serum concentration were observed. The A-2518G polymorphism in MCP-1 gene does not seem to be a risk factor for the development of AD, but its presence correlates with higher levels of serum MCP-1, which can contribute to increase the inflammatory process occurring in AD.

Original languageEnglish
Pages (from-to)1169-1173
Number of pages5
JournalNeurobiology of Aging
Issue number9
Publication statusPublished - Oct 2004


  • Alzheimer's disease
  • Chemokines
  • Genetics
  • MCP-1
  • Monocyte chemoattractant protein-1
  • Polymorphism

ASJC Scopus subject areas

  • Clinical Neurology
  • Biological Psychiatry
  • Developmental Neuroscience
  • Neurology
  • Psychology(all)


Dive into the research topics of 'MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels'. Together they form a unique fingerprint.

Cite this